Challenges of clinical trial design for targeted agents against pediatric leukemias. - Wikidata - awgldk - TriplyDB

Challenges of clinical trial design for targeted agents against pediatric leukemias.

Challenges of clinical trial design for targeted agents against pediatric leukemias.

http://www.wikidata.org/entity/Q34839887

about

The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia Innovations for phase I dose-finding designs in pediatric oncology clinical trials.The biomarkers of leukemia stem cells in acute myeloid leukemia.

P2860

Q36267151-FC50A095-F210-402B-82FF-E00F6CD4C6A7 Q36757843-7144D3C2-1F08-46A1-ADC8-E7EB1F08738C Q39265778-C3695FDA-6939-45F2-B964-EAB690D00FFB

P2860

Challenges of clinical trial design for targeted agents against pediatric leukemias.

http://www.wikidata.org/entity/Q34839887

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@ast

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@en

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@nl

type

label

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@ast

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@en

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@nl

prefLabel

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@ast

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@en

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@nl

P1433

Q34839887-D37480D3-A907-406D-B2B9-2BBA7FA008AE

P1476

Q34839887-9AAB87F4-E948-4FE5-980D-3522DD51C825

P2093

Q34839887-85FDDD96-8D5D-4B2C-83C2-D5B554AEA98C

P2860

Q34839887-007DB7B4-F054-4475-804C-2E0F0143C89C

Q34839887-0E1E3281-44A3-4743-9B1D-8988B37B1E69

Q34839887-13EA7922-A140-4DDB-B3D3-F352E3751438

Q34839887-143EDB92-C103-45B0-98B2-154A698AE902

Q34839887-1567F3B3-6410-45B6-9E4A-A2627D7AFF0B

Q34839887-1BC726E7-EF18-4A73-8A08-0E84E4293C5A

Q34839887-270E6DC5-FA81-422A-8103-B1261F2DABAE

Q34839887-2CC288EB-F230-4610-AF52-C67C6ED8971B

Q34839887-2D79C625-3889-4935-9879-9F353D762EEC

Q34839887-3534A896-DBD4-4FE5-8B7B-B7AF8916D687

P304

Q34839887-99A4E400-BEA4-4687-A173-F0E02360F0E6

P31

Q34839887-9A8C3CC4-861D-4430-BCB1-A5CF56842454

P356

Q34839887-42DD275A-A9EB-4517-ACA4-6CAEFC8C900B

P478

Q34839887-771FDDC6-7F36-4047-A403-9E38DC58030C

P50

Q34839887-28A839FE-D587-43FB-BB29-00A2A9C8EEB6

Q34839887-C2DF9791-28D6-4D5B-89BC-785A4418D615

Q34839887-F58FFF22-E52E-4DF6-8D44-D0D521C3EF18

P577

Q34839887-1E184A0E-0A6E-4F20-A70C-B6CB75D2371F

P5875

Q34839887-D1900F5B-302B-4A8C-9A2B-CD786D249D1F

P698

Q34839887-B468A504-FF81-4574-86F7-434204305765

P932

Q34839887-9DDAE338-531F-485D-B3F3-0550BAFA6F57

P356

FONC.2014.00374

P1433

Frontiers in Oncology

P1476

Challenges of clinical trial design for targeted agents against pediatric leukemias.

@en

P2093

Christopher Mitchell

http://www.w3.org/2001/XMLSchema#string

P2860

Design of Phase II cancer trials evaluating survival probabilities

Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study

Use of historical control data for assessing treatment effects in clinical trials.

Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells.

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

P304

374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2014.00374

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Francis Jay Mussai

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271331692

http://www.w3.org/2001/XMLSchema#string

P698

25610810

http://www.w3.org/2001/XMLSchema#string

P932

4285052

http://www.w3.org/2001/XMLSchema#string